Rituxan Hycela | Rituximab And Hyaluronidase Injection while Breastfeeding
Modern medicine has evolved so much so that sooner or later every breastfeeding mother needs to take it in one form or other. Medication that is present in mothers blood will transfer into her breast milk to some extent. Most drugs do so at low levels and pose no real risk to infants but then there are some exceptions. In This post will discuss whether Rituxan Hycela | Rituximab And Hyaluronidase Injection is safe in breast-feeding or not.

What is Rituxan Hycela | Rituximab And Hyaluronidase Injection used for?


RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) (1.1) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) (1.2) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) (1.3) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion. (1.4, 2.1 , 5.4). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. (1.4) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. 1.2 Diffuse Large B-Cell Lymphoma (DLBCL) RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 1.3 Chronic Lymphocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL. 1.4 Limitations of Use Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion [see Dosage and Administration (2.1) and Warnings and Precautions (5.4)]. RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.

Is Rituxan Hycela | Rituximab And Hyaluronidase Injection safe to use while breastfeeding? Can it interfere with growth and development of my kid?

Rituxan Hycela | Rituximab And Hyaluronidase Injection low risk for breastfeeding
Rituximab and Hyaluronidase (human recombinant) are the two main ingredients of Rituxan Hycela | Rituximab And Hyaluronidase Injection. Based on our individual analysis of Rituximab and Hyaluronidase (human recombinant) we can safely say that Rituxan Hycela | Rituximab And Hyaluronidase Injection has low risk while breastfeeding. Below we have summarized the usage of Rituximab and Hyaluronidase (human recombinant) while breastfeeding, we recommend you to go through it for better understanding of your usage.

Rituxan Hycela | Rituximab And Hyaluronidase Injection Breastfeeding Analsys


Rituximab while Breastfeeding

Low Risk

CAS Number: 174722-31-7

Monoclonal antibody which is an immunoglobulin G with anti-CD20 activity that contains 664 amino acids. Indicated for treatment of Rheumatoid Arthritis, Hodgkin Lymphoma and Chronic Lymphoid Leukemia. At latest update relevant data on breastfeeding were not found. Because of a high molecular weight, excretion into breast milk is very unlikely. Its low oral bioavailability makes that serum levels in the infant that could be originated from milk absorption are to be absent or scanty, except in premature infants or in the early period after birth in which gut absorption may be increased. Many reports have not shown harmful effects in the infant after long-lasting intrauterine exposure . However, despite it is thought to be safe while breastfeeding, and, until more data on this drug is available, in cases of Rheumatoid Arthritis a known safer alternative should be used.

Hyaluronidase (human recombinant) while Breastfeeding

Safe

CAS Number: 9001-54-1

Enzyme obtained from testes of mammals that acts by depolymerization of mucopolysaccharides like hyaluronic acid. It is used to facilitate the diffusion of local anesthetics.

Rituxan Hycela | Rituximab And Hyaluronidase Injection Breastfeeding Analsys - 2


Rituximab while Breastfeeding

CAS Number: 174722-31-7

Is Rituxan Hycela | Rituximab And Hyaluronidase Injection safe while breastfeeding

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that targets CD20, a B-cell-specific surface antigen. Limited data indicate that the amount in milk is very low and absorption is unlikely because it is a protein with a molecular weight of 143,860, it is probably destroyed in the infant's gastrointestinal tract.[1][2] Although 2 breastfed infants apparently experienced no adverse effects during maternal use of rituximab, no long-term data are available. If rituximab is required by the mother, it is not a reason to discontinue breastfeeding.[3] Until more data become available, rituximab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.[4][5][6] The manufacturer recommends that breastfeeding be discontinued during rituximab therapy and for 6 months after the last dose.


I am nursing mother and I have already used Rituxan Hycela | Rituximab And Hyaluronidase Injection, what should I do?

During whole lactation period you shall first discuss with your doctor and then together you shall decide whether you shall take that drug or not however if you have already taken Rituxan Hycela | Rituximab And Hyaluronidase Injection then you shall inform your doctor, But you should not be worried too much as Rituxan Hycela | Rituximab And Hyaluronidase Injection comes in category of low risk drug.


My health care provider has asked me to use Rituxan Hycela | Rituximab And Hyaluronidase Injection, what to do?

Though Rituxan Hycela | Rituximab And Hyaluronidase Injection dose not comes in category of safe drugs rather it comes in category of low risk but if your doctor is aware that you are breastfeeding your baby and has still recommended it then its advantages must be outweighing the risks.


If I am using Rituxan Hycela | Rituximab And Hyaluronidase Injection, will my baby need extra monitoring?

Not much


Who can I talk to if I have questions about usage of Rituxan Hycela | Rituximab And Hyaluronidase Injection in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week